Syncom Formulations (India) Limited (NSE:SYNCOMF)

Market Cap	12.74B -27.8%
Revenue (ttm)	4.89B +5.2%
Net Income	764.38M +54.6%
EPS	0.81 +54.0%
Shares Out	n/a
PE Ratio	16.66
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,168,889
Open	13.55
Previous Close	13.57
Day's Range	13.12 - 13.60
52-Week Range	10.21 - 18.93
Beta	0.73
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About NSE:SYNCOMF

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 744
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SYNCOMF

Financial Performance

In fiscal year 2026, NSE:SYNCOMF's revenue was 4.89 billion, an increase of 5.20% compared to the previous year's 4.65 billion. Earnings were 764.38 million, an increase of 54.62%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 22, 2026

Data Sources Report a data error